pembrolizumab

Documents about pembrolizumab

• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %#982245ClinicalTrials.gov
• Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC#879111ClinicalTrials.gov
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma#471437ClinicalTrials.gov
• Olinvacimab With Pembrolizumab in Patients With mTNBC#847330ClinicalTrials.gov
• KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer#902798ClinicalTrials.gov
• Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive#871129ClinicalTrials.gov
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma#918108ClinicalTrials.gov
• Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer#876089ClinicalTrials.gov
• Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients#981850ClinicalTrials.gov
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)#290967ClinicalTrials.gov
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients#848577ClinicalTrials.gov
• Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma#810182ClinicalTrials.gov
• TATE and Pembrolizumab (MK3475) in mCRC and NSCLC#966140ClinicalTrials.gov
• Palbociclib and Pembrolizumab in Sarcoma#651238ClinicalTrials.gov
• Pembrolizumab Plus Y90 Radioembolization in HCC Subjects#846917ClinicalTrials.gov
• Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer#249581ClinicalTrials.gov
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients#830170ClinicalTrials.gov
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer#845458ClinicalTrials.gov
• Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma#892954ClinicalTrials.gov
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)#900221ClinicalTrials.gov
• A Study of Pembrolizumab and Cryoablation in People With Mesothelioma#908127ClinicalTrials.gov
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma#803882ClinicalTrials.gov
• Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma#838825ClinicalTrials.gov
• A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum#914799ClinicalTrials.gov
• Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)#444864ClinicalTrials.gov
• Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors#810484ClinicalTrials.gov
• Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma#833297ClinicalTrials.gov
• Perioperative Chemo and Pembrolizumab in Gastric Cancer#841088ClinicalTrials.gov
• Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)#857700ClinicalTrials.gov
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer#917821ClinicalTrials.gov
• Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')#979345ClinicalTrials.gov
• Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer#67878ClinicalTrials.gov
• Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer#174877ClinicalTrials.gov
• Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma#838257ClinicalTrials.gov
• Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma#906696ClinicalTrials.gov
• Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer#915492ClinicalTrials.gov
• Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL#916371ClinicalTrials.gov
• Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer#1008490ClinicalTrials.gov
• HDCRT Plus Pembrolizumab in Advanced Malignancies#154656ClinicalTrials.gov
• Pembrolizumab for Newly Diagnosed Glioblastoma#249600ClinicalTrials.gov
• Pembrolizumab in Early Stage Colon Cancer#249618ClinicalTrials.gov
• BO-112 With Pembrolizumab in Unresectable Malignant Melanoma#432893ClinicalTrials.gov
• Breast Cancer Study of Preoperative Pembrolizumab + Radiation#448263ClinicalTrials.gov
• Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.#261490ClinicalTrials.gov
• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers#802272ClinicalTrials.gov
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia#845381ClinicalTrials.gov
• Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide#902685ClinicalTrials.gov
• APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma#914053ClinicalTrials.gov
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer#303650ClinicalTrials.gov
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype#850523ClinicalTrials.gov